MX371295B - Formación de imágenes por irm de placas amiloides usando liposomas. - Google Patents

Formación de imágenes por irm de placas amiloides usando liposomas.

Info

Publication number
MX371295B
MX371295B MX2017004695A MX2017004695A MX371295B MX 371295 B MX371295 B MX 371295B MX 2017004695 A MX2017004695 A MX 2017004695A MX 2017004695 A MX2017004695 A MX 2017004695A MX 371295 B MX371295 B MX 371295B
Authority
MX
Mexico
Prior art keywords
liposomes
mri imaging
amyloid plaque
imaging
aromatic
Prior art date
Application number
MX2017004695A
Other languages
English (en)
Spanish (es)
Other versions
MX2017004695A (es
Inventor
srivastava Mayank
A Tanifum Eric
Annapragada Ananth
Original Assignee
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Childrens Hospital filed Critical Texas Childrens Hospital
Publication of MX2017004695A publication Critical patent/MX2017004695A/es
Publication of MX371295B publication Critical patent/MX371295B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017004695A 2014-10-08 2015-10-08 Formación de imágenes por irm de placas amiloides usando liposomas. MX371295B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US201562111057P 2015-02-02 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Publications (2)

Publication Number Publication Date
MX2017004695A MX2017004695A (es) 2018-01-24
MX371295B true MX371295B (es) 2020-01-24

Family

ID=55653789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004695A MX371295B (es) 2014-10-08 2015-10-08 Formación de imágenes por irm de placas amiloides usando liposomas.

Country Status (10)

Country Link
US (4) US9744251B2 (cg-RX-API-DMAC7.html)
EP (3) EP3204051B1 (cg-RX-API-DMAC7.html)
JP (1) JP6505235B2 (cg-RX-API-DMAC7.html)
KR (1) KR102409017B1 (cg-RX-API-DMAC7.html)
CN (1) CN107106708B (cg-RX-API-DMAC7.html)
AU (2) AU2015330824A1 (cg-RX-API-DMAC7.html)
CA (1) CA2963941C (cg-RX-API-DMAC7.html)
ES (2) ES3032054T3 (cg-RX-API-DMAC7.html)
MX (1) MX371295B (cg-RX-API-DMAC7.html)
WO (1) WO2016057812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012139080A2 (en) 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
WO2013110013A1 (en) 2012-01-20 2013-07-25 Annapragada, Ananth Methods and compositions for objectively characterizing medical images
MX371295B (es) 2014-10-08 2020-01-24 Texas Childrens Hospital Formación de imágenes por irm de placas amiloides usando liposomas.
US10865207B2 (en) 2016-07-22 2020-12-15 Ac Immune S.A. Compounds for imaging Tau protein aggregates
WO2018015549A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
EP3512570B1 (en) 2016-09-16 2024-08-28 Texas Children's Hospital Liposomal gadolinium (gd) contrast agent for t1-mri
EP3548002B1 (en) * 2016-11-30 2025-04-30 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
US20210008204A1 (en) * 2018-03-29 2021-01-14 Microvascular Therapeutics LLC Compositions and methods of detecting and treating alzheimer's disease
CA3102038A1 (en) 2018-06-08 2019-12-12 Ac Immune Sa Novel compounds for diagnosis
US20200261605A1 (en) * 2019-01-24 2020-08-20 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
KR20220054288A (ko) * 2019-07-08 2022-05-02 알제카 바이오사이언시스, 엘엘씨 타우 병리를 위한 표적화 리간드
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
KR102546470B1 (ko) * 2020-01-29 2023-06-21 텍사스 칠드런스 하스피탈 아밀로이드 침착의 mri용 표적 조영제
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
JP2023514991A (ja) * 2020-02-12 2023-04-12 テキサス チルドレンズ ホスピタル α－シンヌクレイン沈着物のＭＲＩのための標的造影剤
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
CA2185810A1 (en) 1994-03-28 1995-10-05 Jo Klaveness Liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
ATE287700T1 (de) 1999-11-30 2005-02-15 Univ Arizona Strahlung-sensitive liposomen
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US6821504B2 (en) 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
JP2005519129A (ja) 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
ATE493152T1 (de) 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
CA2626005A1 (en) 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20070160658A1 (en) 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
WO2009015397A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
AU2008331764A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP2012520898A (ja) 2009-03-19 2012-09-10 マーヴァル バイオサイエンシーズ，インコーポレイテッド 画像化におけるコントラスト強調のための組成物および方法
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
ES2526124T3 (es) * 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
JP5998158B2 (ja) 2011-03-02 2016-09-28 センスリン，エルエルシー ベシクル組成物
WO2012139080A2 (en) * 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013110013A1 (en) 2012-01-20 2013-07-25 Annapragada, Ananth Methods and compositions for objectively characterizing medical images
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
AU2014240042C1 (en) * 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
MX371295B (es) 2014-10-08 2020-01-24 Texas Childrens Hospital Formación de imágenes por irm de placas amiloides usando liposomas.

Also Published As

Publication number Publication date
US20200069820A1 (en) 2020-03-05
WO2016057812A1 (en) 2016-04-14
CN107106708B (zh) 2021-06-18
US10537649B2 (en) 2020-01-21
JP6505235B2 (ja) 2019-04-24
ES3032054T3 (en) 2025-07-15
EP3204051A1 (en) 2017-08-16
AU2021203388A1 (en) 2021-06-24
US20160101197A1 (en) 2016-04-14
US9744251B2 (en) 2017-08-29
AU2015330824A1 (en) 2017-05-25
HK1243335A1 (zh) 2018-07-13
EP4035688C0 (en) 2025-03-26
EP4035688A1 (en) 2022-08-03
CA2963941C (en) 2023-08-01
EP3542828A1 (en) 2019-09-25
EP3204051B1 (en) 2019-05-29
KR102409017B1 (ko) 2022-06-16
MX2017004695A (es) 2018-01-24
EP4035688B1 (en) 2025-03-26
CA2963941A1 (en) 2016-04-14
US11141495B2 (en) 2021-10-12
BR112017007238A2 (pt) 2018-01-16
EP3204051A4 (en) 2018-06-27
ES2743704T3 (es) 2020-02-20
AU2021203388B2 (en) 2024-05-30
KR20170103748A (ko) 2017-09-13
JP2017532378A (ja) 2017-11-02
US20170080111A1 (en) 2017-03-23
CN107106708A (zh) 2017-08-29
US20200179540A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
MX371295B (es) Formación de imágenes por irm de placas amiloides usando liposomas.
IL282995A (en) Formulations of lipid nanoparticles
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
ZA201807871B (en) Methods for making ultrasound contrast agents
MX2013011231A (es) Nanoparticulas basadas en lipidos.
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
WO2016183223A3 (en) Targeted protein contrast agents, methods of making, and uses thereof
WO2012116196A3 (en) Substituted lactosyl compounds and use thereof for cellular imaging and therapy
EP3399965A4 (en) PROLIPOSOMAL TESTOSTERONE ANDECANOATE FORMULATIONS
WO2016094374A8 (en) Compositions and methods for treatment of friedreich's ataxia
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
IL264040A (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
JP2015208317A5 (cg-RX-API-DMAC7.html)
GB201615913D0 (en) Angler's seat box
EP3302579A4 (en) Iron stabilized micelles as magnetic contrast agents
IN2013MU02813A (cg-RX-API-DMAC7.html)
HK40050182A (en) Lipid nanoparticle formulations
HK40050187A (en) Lipid nanoparticle formulations
GB201600833D0 (en) The procedure for restoration of metabolism and new formula of 15 proteins
HK40022834B (zh) 治疗阿尔茨海默病的组合物和方法
HK40028247A (en) Methods for the preparation of liposomes comprising drugs

Legal Events

Date Code Title Description
FG Grant or registration